Vaxart Q1 revenue more than doubles on government contracts

Vaxart

07/05/2026 21:58

Overview

US oral vaccine developer's Q1 revenue more than doubled yr/yr, driven by government contracts

Net income for Q1 turned positive, with basic EPS at $0.02

Company entered share purchase agreement for up to $25 mln common stock over 24 months

Outlook

Company anticipates topline Phase 2b COVID-19 sentinel cohort data in Q2 2026

Vaxart expects primary efficacy and safety data from main COVID-19 cohort in early 2027

Company expects cash runway into second quarter of 2027

Result Drivers

GOVERNMENT CONTRACTS - Revenue growth in Q1 was mainly due to government contracts, especially the BARDA COVID-19 contract

COLLABORATION REVENUE - Q1 revenue included contributions from the Dynavax license and collaboration agreement signed in November 2025

LOWER OPERATING EXPENSES - Decreases in research and development and general and administrative expenses, mainly from lower personnel and facility costs, supported the swing to net income

Company press release: ID:nGNX6jBK1J

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Basic EPS
$0.02


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Vaxart Inc is $4.00, about 436.9% above its May 6 closing price of $0.75

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)